Springer Nature
Browse
Source Data.xlsx (5.26 MB)

Data supporting figures, tables and supplementary information in the published article: Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Download (5.26 MB)
dataset
posted on 2020-03-26, 17:40 authored by Xiuyuan Ou, Yan Liu, Xiaobo Lei, Pei Li, Dan Mi, Lili Ren, Li Guo, Ruixuan Guo, Ting Chen, Jiaxin Hu, Zichun Xiang, Zhixia Mu, Xing Chen, Jieyong Chen, Keping Hu, Qi Jin, Jianwei Wang, Zhaohui Qian
This dataset comprises a single Excel .xlsx spreadsheet with 29 tabs. The data are western blot images and quantitative data characterising spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. The data underlie the figures, table and supplementary figures of the related manuscript.

The 29 tabs are as follows. (NOTE: Western blot images do not display in figshare viewer: please download the spreadsheet to view these)
- Western blots for incorporation of SARS-CoV-2 S protein into pseudovirions.
(Figure 1B, Figure 1C, Figure 1D, Figure 1E, Figure 1F, Figure 1G, Figure 1H, Figure 1I, Figure 1J)
- Entry and receptor of SARS-CoV-2 S pseudovirons.
(Figure 2A, Figure 2B, Figure 2D)
- Endocytosis of SARS-CoV-2 S pseudovirions on 293/hACE2 cells.
(Figure 3A, Figure 3B, Figure 3C, Figure 3D, Figure 3E, Figure 3F)
- Activation of SARS-CoV-2 S protein by cathepsin and trypsin.
(Figure 4A, Figure 4C, Figure 4D, Figure 4E)
- Characterization of polyclonal rabbit anti-SARS S1 antibodies T62.
(Figure 5B, Figure 5E)
- Limited cross-neutralization of SARS-CoV and COVID-19 sera.
(Figure 6A, Figure 6B)
- Neutralization activities of antisera from SARS-CoV and COVID-19 patients.
(Table 1)
- Treatment of cells with 130, a TRPML1 inhibitor.
(Supplementary Figure 1)
- Expressing type II membrane serine protease (TMPRSS) 2, 4, 11A, 11D, and 11E on 293/hACE2 cells.
(Supplementary Figure 3).

In the related publication, the authors use a lentiviral pseudotype system and determine cell type susceptibility, virus receptor, entry pathway and protease priming for SARS-CoV-2. They also identify several potential drug targets for SARS-CoV-2.

Funding

This work was supported by grants from Chinese Science and Technology Key Projects (2020YFC0841000), National Natural Science Foundation of China (31670164 and 31970171 to ZQ, and 81930063 to JW), Chinese Science and Technology Key Projects (2017ZX0103004), COVID-19 Emergency Fund from CAMS (2020HY320001), and the CAMS Innovation Fund for Medical Sciences (2016-12M-1-014 to JW).

History

Research Data Support

Research data support provided by Springer Nature